ArriVent BioPharma Inc. C... (AVBP)
19.48
-0.06 (-0.31%)
At close: Mar 21, 2025, 3:59 PM
19.99
2.64%
After-hours: Mar 21, 2025, 05:16 PM EDT
-0.31% (1D)
| Bid | 19.1 |
| Market Cap | 662.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -81.53M |
| EPS (ttm) | -2.56 |
| PE Ratio (ttm) | -7.61 |
| Forward PE | -8.24 |
| Analyst | Buy |
| Ask | 21.1 |
| Volume | 193,321 |
| Avg. Volume (20D) | 168,629.8 |
| Open | 19.31 |
| Previous Close | 19.54 |
| Day's Range | 19.19 - 20.38 |
| 52-Week Range | 14.35 - 36.37 |
| Beta | 1.02 |
About AVBP
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-sele...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2024
Employees 52
Stock Exchange NASDAQ
Ticker Symbol AVBP
Website https://www.arrivent.com
Analyst Forecast
According to 6 analyst ratings, the average rating for AVBP stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 95.07% from the latest price.
Stock Forecasts4 months ago
-11.86%
ArriVent BioPharma shares are trading lower. The c...
Unlock content with
Pro Subscription
